Since the results showed that the co-administration of an EZH2 inhibitor with gefitinib sensitized the EGFR-WT NSCLC cells to gefitinib, we further investigated the influence of this treatment on cell apoptosis by flow cytometry analysis. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.